Johnson & Johnson's (JNJ) better-than-expected Q2 results and raised full-year outlook are seen as "encouraging" versus the current macro environment, RBC Capital analysts said in a Wednesday note.
The drugmaker is also well-positioned to meet or exceed its full-year guidance as its pharmaceutical and medtech businesses continue to grow, the analysts said.
Growth in core drugs such as Darzalex, Tremfya, and Erleada and share gains in medtech, are expected to sustain revenue through year-end, the firm said.
RBC said that the company's innovation pipeline and broad-based execution support long-term confidence in its outlook.
RBC raised its price target to $185 from $181 and maintained an outperform rating on the stock.
Price: 163.01, Change: -1.77, Percent Change: -1.07
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。